Projects In Knowledge - Gastroenterology

Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities

Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chair this free, yearlong CME/CE program featuring the very latest information on screening and current and emerging treatment strategies for HBV management. Get clarity and guidance from prominent hepatology experts on key issues and practice challenges, including how cultural differences can affect physician/patient communications, thus impacting the management of HBV infection. Earn CME/CE credit and complete all courses to earn your Certificate of Advanced Study....more

A. Di Bisceglie, MD, FACP

R. Gish, MD

The Advanced Certificate Program in Hepatocellular Carcinoma Management

Projects In Knowledge is pleased to present The Advanced Certificate Program in Hepatocellular Carcinoma. This program offers CME and CE credit to oncologists, gastroenterologists, hepatologists, radiologists, surgeons, and other clinicians involved in the care of patients with hepatocellular carcinoma....more

G. Davis, MD

J. Geschwind, MD

Hepatitis C — Social Media, HCV, and the Gastroenterologist

I. Jacobson, MD

Hepatitis C — Game Changers in Hepatology—Future Challenges in the Treatment of HCV

What will your practice look like in the coming years? Watch Game Changers in Hepatology—Future Challenges in the Treatment of HCV,, an on-demand rebroadcast of a recent CME/CE satellite symposium, chaired by Dr. Ira Jacobson, during which Rosemarie Nelson, a nationally known healthcare consultant, will interpret system-wide changes on the healthcare horizon, such as electronic medical records and new reimbursement structures, for the hepatology practice. Drs. Bruce Bacon and Nezam Afdhal will expand on how increasingly complex therapeutic regimens fit within the new healthcare paradigm.
...more

I. Jacobson, MD

Hepatitis C — Brainstorming with the Experts: Practical Approaches to the Complex World of HCV

This stimulating and thought-provoking webcast features a renowned faculty panel—led by Ira Jacobson, MD—who shape their experience and the latest research data into presentations that clarify the state of the science. Moderating is Ira Flatow, host of Talk of the Nation: Science Friday^® on National Public Radio, who practices his notable art of transforming science into discussion. The result: science made useable, complexity made manageable....more

I. Flatow,

I. Jacobson, MD

Colorectal Cancer — The Art of Individualized Treatment in the Management of Colorectal Cancer

Managing a patient with colorectal cancer is increasingly a matter of individualized treatment, and it requires that the clinician have current knowledge not only of therapies, but also the underlying molecular biology. This complex topic is summarized in an on-demand, interactive webcast with a case study, presented by three noted clinical oncologists. Jeffrey A. Meyerhardt, MD, MPH, of Harvard Medical School/Dana-Farber Cancer Institute, Alan Venook, MD, of UCSF, and Richard M. Goldberg, MD, of the University of North Carolina, review and summarize the pertinent scientific and therapeutic data. Throughout, you have the opportunity to add your own input on appropriate management and compare your answers with those of your colleagues....more

R. Goldberg, MD

Hepatitis B — An Interactive Case-Based Approach to Targeted Therapies for GIST

Dr. Richard M. Goldberg moderates a discussion with gastrointestinal stromal tumor (GIST) experts, Charles D. Blanke, MD, and Margaret von Mehren, MD, who present and discuss the case of a 64-year-old woman with metastatic GIST. Through this case, they illustrate how current diagnosis is informed by recent knowledge of the oncogenesis of GIST. They also talk about the implications of new data with regard to selecting and optimizing targeted therapies for first- and second-line treatment in metastatic disease. Emerging concepts such as adjuvant treatment with targeted therapies, use of genotyping to tailor dosing, and prevention and management of resistance to targeted therapies are explored. Throughout, you will be provided with the opportunity to add your own input on appropriate management and compare your answers with those of your colleagues....more

Hepatitis B — Hepatitis C: From Scientific Foundations to New Vistas in Treatment

...more

I. Jacobson, MD

Hepatitis B — Who Moved My PEG? The Changing Future of Anti-HCV Therapy

The times, they are a-changin'—so is the way we manage HCV infection. Join us as we examine the future direction of anti-HCV therapy and help clinicians embrace the changes ahead....more

Hepatitis B — Expert Insight Into: Severe Lactic Acidosis During Treatment of Chronic Hepatitis B with a Nucleoside Analog in Patients with Impaired Liver Function (Part 8 of Series)

Because of their high efficacy and barrier to resistance, entecavir and tenofovir are recommended for the treatment of chronic hepatitis B patients with advanced fibrosis or cirrhosis. Although these drugs have few side effects in patients with normal liver function, little is known about the side effect profiles in patients with impaired liver function. Dr. Tram Tran discusses the occurrence of lactic acidosis in a series of chronic hepatitis B patients with impaired liver function being treated with entecavir....more

T. Tran, MD

Hepatitis B — Case Study: Focus on Reactivation

Learn from Dr. Adrian M. Di Bisceglie as he follows the case of a 45-year-old Greek immigrant with Crohn’s disease. A key consideration prior to starting infliximab, a monoclonal antibody against tumor necrosis factor (TNF) alpha, is the potential for hepatitis B reactivation. This case will model what to do before, during, and after anti-TNF therapy. “Focus on Reactivation” is one course in the The Advanced Certificate Program in Chronic Hepatitis B Management V: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities....more

A. Di Bisceglie, MD, FACP

Colorectal Cancer — Expert Insight Into: Incidence and Risk Factors of Progression to Cirrhosis in Inactive Carriers of Hepatitis B Virus (Part 5 of Series)

In this course, Dr. Mindie Nguyen discusses a study of inactive HBV carriers enrolled from 1980 to 2005 in Taiwan, a region with a high prevalence of HBV infection. The study estimated the incidence of cirrhosis at up to 25 years of follow-up and identified risk factors associated with progression to cirrhosis....more

M. Nguyen, MD, MAS

Hepatitis B — Case Study: Focus on Basic Disease Management (the "Grey Zone" Patient)

In this case-based e-newsletter, Tram T. Tran, MD, follows the case of a Chinese-born man in his mid-forties who receives a diagnosis of chronic hepatitis B. His serologic, virologic, and biochemical markers at the time of presentation place him in the grey-zone category between “Treat” and “Don’t Treat” according to current treatment guidelines. Join Dr. Tran as she demonstrates the decision-making processes for starting treatment in this patient and for interpreting response as his on-treatment HBV DNA levels fail to become undetectable. This course is part of Advanced Certificate Program V: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities....more

R. Gish, MD

Hepatitis C — Social Media, HCV, and the Gastroenterologist

I. Jacobson, MD

Hepatitis B — Expert Insight Into: Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-Up Study (Part 4 of Series)

Hepatocellular carcinoma is often associated with HBV infection. In July 1984, Taiwan began a universal HBV vaccination program that has succeeded in reducing the incidence of hepatocellular carcinoma in children. Dr. Adrian Di Bisceglie discusses a study based on the Taiwan HBV vaccination program that investigated whether the protection from hepatocellular carcinoma extends into early adulthood and, also, what factors predict an increased risk of hepatocellular carcinoma among vaccinees....more

A. Di Bisceglie, MD, FACP

Hepatitis B — Expert Insight Into: Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008 (Part 3 of Series)

The CDC recommends testing for chronic HBV infection for all foreign-born individuals from regions with a prevalence rate of 2% or greater, but recent data on the prevalence of HBV are lacking. Dr. Tram Tran discusses a study that provided updated estimates of the prevalence of chronic HBV infection in refugees entering the United States from various countries of origin....more

T. Tran, MD

Colorectal Cancer — Expert Insight Into: Treatment with an Anti-VEGF Monoclonal Antibody Beyond First Progression is Associated with Prolonged Overall Survival in Metastatic Colorectal Cancer: Results from a Large Observational Cohort Study (BRiTE)

Patients with mCRC have improved overall and progression-free survival in response to bevacizumab when it is offered as part of first- or second-line treatment. However, little is known of the clinical benefits or potential risks that can result from its prolonged use. Join Dr. Cathy Eng as she reports on a large observational study that examined safety and overall and progression-free survival associated with bevacizumab + chemotherapy given after initial disease progression on a bevacizumab-containing regimen....more

C. Eng, MD

Hepatitis B — Expert Insight Into: Hepatitis B Testing and Vaccination Among Vietnamese- and Cambodian-Americans (Part 2 of Series)

Owing to the high endemic rate of HBV infection in Southeast Asia, the CDC provides recommendations for HBV testing and vaccination of Southeast Asians living in the United States. Dr. Robert Gish discusses a recent survey that examined rates of HBV testing and vaccination among Vietnamese Americans and Cambodian Americans in four US communities and comments on the need to more effectively reach these populations if prevention and management of HBV are to be improved....more

R. Gish, MD

Hepatitis B — Case Study: Focus on Screening and Testing

Identifying persons with chronic HBV infection enables them to receive treatment and prevent transmission to others. In this case presentation of a man whose parents were born in China, Dr. Calvin Pan takes you through the HBV screening and evaluation process, addressing key issues including whom to screen, what tests to order, and how to interpret test results. This Tx Reporter e-newsletter is the first of four in Advanced Certificate Program V: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities....more

A. Di Bisceglie, MD, FACP